PRME ▲ +0.7% - Prime Medicine, Inc.
$PRME - Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson Disease
05-OCT-2026 08:00 AM ET
Share this post
More filings for $PRME
PRME - Prime Medicine, Inc. - SEC Filing Update (13-NOV-2026) | ThinkSabio - Stocks SimplifiedNov 13, 2026PRME - Prime Medicine, Inc. - SEC Filing Update (13-NOV-2026) | ThinkSabio - Stocks SimplifiedNov 13, 2026PRME ▼ -9.5% - Prime Medicine, Inc.Nov 12, 2026PRME ▼ -9.3% - Prime Medicine, Inc.Nov 12, 2026PRME ▼ -12.1% - Prime Medicine, Inc.Nov 11, 2026PRME ▼ -8.9% - Prime Medicine, Inc.Nov 10, 2026
View full $PRME filing history →💬 Comments
Loading comments…
Leave a comment